Navigation Links
AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference

CASTLE ROCK, Colo., Feb. 14 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (Nasdaq: APPY) an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, has been invited to present at the 20th Annual Roth Capital Partners Growth Stock Conference. The conference will be held February 18-21, 2008 at the Ritz Carlton Laguna Niguel in Dana Point, California.

Roth Capital Partners Stock Conferences are one of the largest in the nation for micro and small-cap companies in technology, healthcare, financial services and consumer products sectors. More than 1,000 institutional investors are expected to attend.

AspenBio's president and CEO, Richard Donnelly, is scheduled to present on Tuesday, February 19 at 3:00 PM Pacific Time (6:00 PM Eastern Time), followed by a break out session and one-on-one meetings. A simultaneous Webcast will be available at

For more information on the Roth conference, please visit the conference website at or call the conference desk at 800-678-9147. For media inquiries and press credentials only call 949-720-5700.

About Roth Capital Partners, LLC

With corporate headquarters in Newport Beach, California and offices in strategic locations in the Western United States and Shanghai, China, Roth Capital Partners, LLC is a full service investment bank serving corporate and institutional clients throughout the world. Offering a wide array of investment banking services including: initial public offerings, follow-ons, PIPEs, private placements, mergers and acquisitions, investment research, and institutional sales and trading, the firm is perhaps best known for finding, funding and fostering the growth of emerging companies. It is a member of the Financial Industry Regulatory Authority, Inc. ("FINRA"), and the Securities Investor Protection Corporation (SIPC). Visit the Roth Capital Partners website at

About AspenBio Pharma, Inc.

AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery; development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma continues to advance the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out appendicitis in patients complaining of abdominal pain. For more information, go to

Investor Relations:

Liolios Group, Inc.

Ron Both

Tel 949-574-3860

SOURCE AspenBio Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AspenBio Pharma Closes $18.2 Million Private Placement of Common Stock
2. AspenBio Pharma Announces $18 Million Private Placement of Common Stock
3. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
4. AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference
5. AspenBio Pharma to Present the Edgewater Research Investor Conference
6. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
7. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
8. AspenBio Pharma Reports Second Quarter 2007 Results
9. Technology Transforms Market Research in Pharmaceutical Industry
10. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast
11. Assured Pharmacy Consolidates Portland, Oregon Pharmacy
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine ... Jurassic World: The Exhibition, opening in March 2016 at Melbourne Museum in Melbourne, ... tour including several North American tour dates. The Exhibition is based on Universal ...
(Date:11/30/2015)... 30, 2015  Aytu BioScience, Inc. (OTCQB: AYTU), a ... conditions, will present at two upcoming investor conferences. Aytu ... real-time virtual conference, to be held December 3, 2015, ... be held December 2 nd & 3 rd ... and streamed live via webcast. Josh Disbrow ...
(Date:11/30/2015)... Israel , Nov. 30, 2015 ... leading developer of adult stem cell technologies for neurodegenerative diseases, ... has been awarded an additional grant of approximately $735,000 from ... (OCS). This grant, the second this year, brings the total ... $1.8 million (approximately NIS7 million).  ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> Accutest Research Laboratories, ... Contract Research Organization (CRO), has formed ... Cancer Center - Temple Health for ... ,     (Photo: ) , ...
Breaking Biology Technology:
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
Breaking Biology News(10 mins):